We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$14.9M
1-Year Est. Return
38.76%
This Fund
S&P 500
This Quarter
Est. Return
+12.4%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$237M
AUM Growth
+$61.7M
(+35%)
Cap. Flow
+$42.4M
Cap. Flow
% of AUM
17.92%
Top 10 Holdings %
Top 10 Hldgs %
29.74%
Holding
101
New
35
Increased
9
Reduced
16
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$7.31M |
| 2 |
Bruker
BRKR
|
+$5.5M |
| 3 |
LivaNova
LIVN
|
+$4.1M |
| 4 |
SPNC
Spectranetics Corp
SPNC
|
+$3.7M |
| 5 |
Cooper Companies
COO
|
+$3.58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stryker
SYK
|
+$5.02M |
| 2 |
Bausch Health
BHC
|
+$4.13M |
| 3 |
CYBX
CYBERONICS INC
CYBX
|
+$3.65M |
| 4 |
Abbott
ABT
|
+$3.22M |
| 5 |
VAR
Varian Medical Systems, Inc.
VAR
|
+$2.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 56.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
AstraZeneca
AZN
$240B
| $8.63M | 3.64% |
+46,250
| New | +$3.03M |
|
2
Cigna
CI
$74.5B
| $8.41M | 3.55% |
57,500
-3,500
| -6% | -$481K |
|
|
3
Baxter International
BAX
$14.5B
| $7.63M | 3.22% |
+200,000
| New | +$7.31M |
|
4
Teleflex
TFX
$6.25B
| $7.23M | 3.05% |
55,000
-2,500
| -4% | -$325K |
|
5
Insulet
PODD
$11.6B
| $7.17M | 3.02% |
189,501
+8,901
| +5% | +$300K |
|
|
6
CALL
Teleflex
TFX
$6.25B
| $6.57M | 2.77% |
50,000
| – | – |
|
|
7
Bruker
BRKR
$9.69B
| $6.43M | 2.71% |
+265,000
| New | +$5.5M |
|
8
Boston Scientific
BSX
$70.9B
| $6.18M | 2.61% |
335,000
-80,000
| -19% | -$1.43M |
|
9
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$805B
| $6.12M | 2.58% |
+30,000
| New | +$6.16M |
|
10
PUT
iShares Biotechnology ETF
IBB
$9.19B
| $6.09M | 2.57% |
+54,000
| New | +$5.86M |
|
11
PUT
First Trust Health Care AlphaDEX Fund
FXH
$1.05B
| $6.04M | 2.55% |
+100,000
| New | +$5.97M |
|
12
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
| $5.97M | 2.52% |
+85,000
| New | +$5.8M |
|
13
Pfizer
PFE
$142B
| $5.89M | 2.49% |
192,355
-13,043
| -6% | -$410K |
|
14
PUT
BioMarin Pharmaceuticals
BMRN
$11.6B
| $5.87M | 2.48% |
+56,000
| New | +$5.85M |
|
15
AbbVie
ABBV
$434B
| $5.63M | 2.38% |
95,000
+21,000
| +28% | +$1.21M |
|
16
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.7B
| $5.4M | 2.28% |
+75,000
| New | +$5.3M |
|
|
ACH
17
Accendra Health
ACH
$260M
| $5.25M | 2.22% |
145,900
+75,900
| +108% | +$2.75M |
|
18
Universal Health Services
UHS
$10.3B
| $5.08M | 2.14% |
42,500
-22,300
| -34% | -$2.73M |
|
19
PUT
Becton Dickinson
BDX
$46.4B
| $4.62M | 1.95% |
+30,750
| New | +$4.43M |
|
|
NXTM
20
DELISTED
NxStage Medical Inc.
NXTM
| $4.6M | 1.94% |
210,000
-100,000
| -32% | -$1.86M |
|
|
WMGI
21
DELISTED
Wright Medical Group Inc
WMGI
| $4.5M | 1.9% |
186,000
-24,101
| -11% | -$522K |
|
|
NUVA
22
DELISTED
NuVasive, Inc.
NUVA
| $4.33M | 1.83% |
80,000
+7,220
| +10% | +$368K |
|
|
SPNC
23
DELISTED
Spectranetics Corp
SPNC
| $4.22M | 1.78% |
+280,266
| New | +$3.7M |
|
|
24
LivaNova
LIVN
$4.45B
| $4.01M | 1.69% |
+67,500
| New | +$4.1M |
|
25
Bristol-Myers Squibb
BMY
$133B
| $3.98M | 1.68% |
57,800
+4,050
| +8% | +$268K |
|
Similar funds
GMP
BCA
ONGA
RC
DOFI
SRA
SR
TC
Pura Vida Investments's Q4 2015 Portfolio in Review
As of Q4 2015, Pura Vida Investments held 101 positions worth $237M, up 35% from $175M the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Pura Vida Investments deployed $42.4M of net new capital in Q4 2015, opening 35 new positions and adding to 9 existing holdings. Its largest new stake was Baxter International: 200,000 shares worth $7.63M.
By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 66% a quarter earlier.
On the sell side, the largest reduction was Stryker, an estimated $5.02M trimmed.
- Pura Vida Investments's largest Q4 2015 buy was Baxter International: 200,000 shares worth $7.63M.
- Pura Vida Investments added most to Accendra Health in Q4 2015, an estimated $2.75M increase.
- Pura Vida Investments's biggest Q4 2015 reduction was Stryker, cutting an estimated $5.02M.
- Pura Vida Investments fully exited Bausch Health in Q4 2015, selling an estimated $4.13M.
- Pura Vida Investments's ten largest holdings make up 30% of its $237M portfolio in Q4 2015.
- Pura Vida Investments opened 35 new positions and closed 26 in Q4 2015.
- Pura Vida Investments's portfolio value rose 35% quarter-over-quarter to $237M.
Based on Pura Vida Investments's 13F filing for Q4 2015, filed 16 Feb 2016.